An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for
certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly
subcutaneous injections for 12 weeks.